Myriad Genetics Inc: (NASD: MYGN)

$25.88

-0.56 (-2.12%)

Volume 2,812,338

Jun 19 04:00 PM ET

Zacks Rank: 1-Strong Buy

#1
 
 
 
 

Income Statements

Get Income Statements for:

Annual Income Statement

Fiscal Year End for MYRIAD GENETICS falls in the month of June .

All items in Millions except EPS data.

06/30/12 06/30/11 06/30/10 06/30/09 06/30/08
Sales 496 402 363 327 334
Cost Of Goods 65 47 44 43 32
Gross Profit 431 355 318 283 301
Selling & Adminstrative & Depr. & Amort Expenses 251 198 183 157 263
Income After Depreciation & Amortization 180 158 135 126 38
Non-Operating Income 4 2 6 10 10
Interest Expense 0 0 0 0 0
Pretax Income 185 160 141 136 48
Income Taxes 72 59 -11 0 1
Minority Interest 0 0 0 0 0
Investment Gains/Losses 0 0 0 0 0
Other Income/Charges 0 0 0 0 0
Income From Cont. Operations 112 101 152 136 48
Extras & Discontinued Operations 0 0 0 -52 0
Net Income 112 101 152 85 48
Depreciation Footnote 06/30/12 06/30/11 06/30/10 06/30/09 06/30/08
Income Before Depreciation & Amortization 189 165 142 136 47
Depreciation & Amortization (Cash Flow) 9 7 7 9 9
Income After Depreciation & Amortization 180 158 135 126 38
Earnings Per Share Data 06/30/12 06/30/11 06/30/10 06/30/09 06/30/08
Average Shares 86.47 91.70 99.15 98.57 93.41
Diluted EPS Before Non-Recurring Items 1.30 1.10 1.39 1.38 0.51
Diluted Net EPS 1.30 1.10 1.54 0.86 0.51

Quarterly Income Statement

Fiscal year end for MYRIAD GENETICS falls in the month of June .

All items in Millions except EPS data.

03/31/13 12/31/12 09/30/12 06/30/12 03/31/12
Sales 156.47 149.14 133.44 132.96 129.78
Cost Of Goods 20.33 19.88 17.32 16.96 17.22
Gross Profit 136.13 129.25 116.11 116.02 112.54
SG&A, R&D, and Dept/Amort Expenses 78.21 73.66 67.52 68.74 66.45
Income After SG&A, R&D, and Dept/Amort Expenses 57.92 55.59 48.59 47.28 46.09
Non-Operating Income 1.32 1.39 1.24 1.20 1.38
Interest Expense 0.00 0.00 0.00 0.00 0.00
Pretax Income 59.24 56.98 49.82 48.48 47.48
Income Taxes 21.34 21.94 19.68 19.34 17.86
Minority Interest 0.00 0.00 0.00 0.00 0.00
Investment Gains/Losses 0.00 0.00 0.00 0.00 0.00
Other Income/Charges 0.00 0.00 0.00 0.00 0.00
Income From Cont. Operations 37.89 35.04 30.14 29.14 29.61
Extras & Discontinued Operations 0.00 0.00 0.00 0.00 0.00
Net Income 37.89 35.04 30.14 29.14 29.61
Earnings Per Share Data 03/31/13 12/31/12 09/30/12 06/30/12 03/31/12
Average Shares 82.36 84.24 83.91 86.32 86.46
Diluted EPS Before Non-Recurring Items 0.46 0.42 0.36 0.34 0.34
Diluted Net EPS 0.46 0.42 0.36 0.34 0.34
 

MYGN Chart by YCharts

Quick Links

Services

My Account

Resources

Client Support

Follow Us

Facebook

Twitter

Linkedin

RSS

You Tube

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.

Copyright 2013 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.

Visit performance for information about the performance numbers displayed above.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.